CypMaster™ CYP450 Reaction Phenotyping Kit (7-Isoform Specific Panel)

Identifies specific CYP450 enzymatic contributions to drug biotransformation using a comprehensive panel of isoform-selective chemical inhibitors.

CypMaster™

ADME

Metabolism

The CypMaster™ CYP450 Reaction Phenotyping Kit (7-Isoform Specific Panel) provides an essential in vitro platform for metabolic mapping. By utilizing seven validated, highly selective inhibitors, this system quantifies the fractional contribution of individual enzymes to total hepatic clearance, facilitating precise predictions of clinical drug-drug interaction risks and metabolic stability.

Isoform Precision: Employs seven rigorously validated, high-selectivity chemical inhibitors to ensure accurate identification of specific enzymatic biotransformation and clearance pathways.
Standardized Methodology: Formulated for seamless integration with liver microsomes, providing a consistent environment for evaluating the kinetics of drug candidate metabolism.
High-Throughput Compatibility: Features a ready-to-use reagent format designed for rapid experimental setup and high-sensitivity downstream analysis via LC-MS/MS platforms.
Reliable Data Quality: Optimized buffer systems and verified inhibitory concentrations minimize off-target effects, ensuring robust and reproducible results for regulatory documentation.

Identifies the specific CYP450 enzymes driving hepatic clearance to predict metabolic liabilities and potential clinical drug-drug interaction risks.

Lead optimization, preclinical ADME characterization, and regulatory-compliant in vitro metabolism and drug interaction studies.

Reaction phenotyping, determination of fm values for major CYPs, metabolic stability assessment, ADME profiling studies, and identifying enzymatic pathways involved in pro-drug activation.

Internal performance validation using reference standards under defined assay conditions.

Seven major human liver CYP450 isoforms

Tissue homogenates, cell lysates, serum, plasma, and other biological fluids.

Quantitative

Pharmacokinetics (ADME), oncology therapeutics, clinical pharmacology, xenobiotic toxicology, etc.

105 tests

Quantitative measurement of isoform-specific inhibition and fractional contribution to total hepatic drug metabolism.

Human

Quantitative

Upon receipt, store the kit in accordance with the storage conditions specified in the product manual.

Avoid repeated freeze-thaw cycles. During use, minimize the time components are exposed to room temperature and return them promptly to -20°C; storage after handling. Do not store at elevated temperatures for extended periods.

12 months under recommended storage conditions to ensure optimal performance.

For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.

For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.

Shipped on ice under temperature-controlled conditions.

Cytochrome P450 enzymes are the primary drivers of Phase I oxidative metabolism. Identifying the specific isoforms involved in drug clearance is essential for managing patient safety and predicting inter-individual variability.

CYP450 enzymes catalyze the oxidation of lipophilic xenobiotics within the hepatic endoplasmic reticulum. This pathway requires electrons from NADPH, transferred via NADPH-cytochrome P450 reductase, to facilitate systemic drug detoxification.